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Abstract: Most of the prescribing and dispensing of medicines happens in primary care.
Pharmacogenomics (PGx) is the study and clinical application of the role of genetic variation
on drug response. Mounting evidence suggests PGx can improve the safety and/or efficacy of several
medications commonly prescribed in primary care. However, implementation of PGx has generally
been limited to a relatively few academic hospital centres, with little adoption in primary care.
Despite this, many primary healthcare providers are optimistic about the role of PGx in their future
practice. The increasing prevalence of direct-to-consumer genetic testing and primary care PGx
studies herald the plausible gradual introduction of PGx into primary care and highlight the changes
needed for optimal translation. In this article, the potential utility of PGx in primary care will be
explored and on-going barriers to implementation discussed. The evidence base of several drug-gene
pairs relevant to primary care will be outlined with a focus on antidepressants, codeine and tramadol,
statins, clopidogrel, warfarin, metoprolol and allopurinol. This review is intended to provide both a
general introduction to PGx with a more in-depth overview of elements relevant to primary care.
Keywords: pharmacogenomics; primary care; adverse drug reaction; implementation; antidepressants;
warfarin; statins; clopidogrel; drug hypersensitivity
1. Introduction
It is increasingly recognised that individuals respond differently to medications. In some cases,
these differences in response can be clinically significant leading to failure of therapy or adverse drug
reactions (ADRs). The aetiology of this inter-individual variability is complex with multiple contributors
including individual characteristics (e.g., age, sex, body mass index), clinical factors (e.g., renal or
hepatic impairment; co-medications), environmental exposures (e.g., smoking) and genetics.
Pharmacogenomics (PGx) is the study of the influence of genetic variation on drug response [1]
with the aim of increasing the efficacy and safety of current and future treatments. Specifically, it aims
to facilitate a move away from the standard empirical trial and error prescribing approach that currently
exists and transition towards a more stratified and precise prescribing paradigm.
It is estimated that there are between 19,000 to 21,000 protein-coding genes present in the human
genome [2]. Within these genes, multiple types of genetic variations can occur including single nucleotide
polymorphisms (SNPs), indels (small insertion/deletions) and larger structural rearrangements; of these,
SNPs are the most common. Pharmacokinetics (PK) describes “what the body does to a drug” and
pharmacodynamics (PD) “what a drug does to the body”. Genomic variation in genes involved in a drug’s
absorption, distribution, metabolism and elimination (e.g., drug-metabolising enzymes or transporters)
can alter a drug’s PK profile, influencing systemic exposure and resulting in altered drug response
(i.e., influencing its downstream PD). Alternatively, genomic variation in genes that modulate a drug’s PD
(e.g., its therapeutic on-target and off-target sites) can directly influence drug response. Importantly, in both
cases, the altered drug response can attenuate a drug’s efficacy or worsen tolerability/safety (Figure 1).
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or increase exposure predisposing often to type A (augmented) adverse drug reactions (ADRs), which 
are ADRs mediated through excessive action on the drug’s therapeutic target and so are predictable 
(e.g., bleeding after excessive warfarinisation). Secondly, genetic polymorphisms in a drug’s 
therapeutic target can directly modulate drug response, leading to reduced effectiveness or type A 
ADRs. Lastly, many small molecule drugs bind with varying affinities to unintended off-target 
molecules, both within and separate to the immune system. Genetic changes in these off-target sites 
can predispose to less predictable and less common type B (bizarre) ADRs. Of particular note, many 
rare but serious type B ADRs, such as drug-induced skin injury and drug-induced liver injury, are 
type IV T-cell mediated delayed type hypersensitivity reactions, and have been very strongly 
associated with specific human leukocyte antigen (HLA) alleles. It should also be noted that changes 
in a drug’s pharmacokinetics leading to increased exposure can, on occasion, predispose to off-target 
(type B) ADRs, as is the case, for example, with simvastatin myotoxicity. 
The clinical and financial consequences of adverse drug reactions (ADRs) are high, accounting 
for an estimated 6.5% of hospital admissions [3]. Interestingly, for several of the drugs often 
implicated in causing hospitalisation, PGx guideline recommendations are now available, such as for 
warfarin, antiplatelet agents and opioid analgesics [4]. In addition to serious ADRs leading to 
hospitalisation, it is also known that poor drug tolerability (for example due to mild adverse events) 
is associated with lower compliance [5], which increases the chances of reduced efficacy and 
increased medicines wastage. 
It is estimated that over 98% of individuals carry at least one pharmacogenetic variant [6]. 
Importantly, the majority of prescribing and dispensing of medicines happens in primary care, and 
recent studies in both the US and UK suggest that over 60% of patients within the primary care setting 
are prescribed a medication with a PGx recommendation [7,8] 
The Dutch Pharmacogenomics Working Group (DPWG) and Clinical Pharmacogenetics 
Implementation Consortium (CPIC) are the two most widely recognised expert groups involved in 
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and/or pharmacodynamics of a drug, with examples of clinically relevant drug-gene pairs.
Genetic changes in drug-metabolising enzymes and transporters can alter a drug’s pharmacokinetics,
influencing its tissue exposure and so affecting its downstream pharmacodynamics. These changes can
lead to underexposure and potentially reduced effectiveness, or increase exposure predisposing often to
type A (augmented) adverse drug reactions (ADRs), which are ADRs mediated through excessive action
on the drug’s therapeutic target and so are predictable (e.g., bleeding after excessive warfarinisation).
Secondly, genetic polymorphisms in a drug’s therapeutic target can directly modulate drug response,
leading to reduced effectiveness or type A ADRs. Lastly, many small molecule drugs bind with
varying affinities to unintended off-target molecules, both within and separate to the immune system.
Genetic changes in these off-target sites can predispose to less predictable and less common type B
(bizarre) ADRs. Of particular note, many rare but serious type B ADRs, such as drug-induced skin injury
and drug-induced liver injury, are type IV T-cell mediated delayed type hypersensitivity reactions,
and have been very strongly associated with specific human leukocyte antigen (HLA) alleles. It should
also be noted that changes in a drug’s pharmacokinetics leading to increased exposure can, on occasion,
predispose to off-target (type B) ADRs, as is the case, for example, with simvastatin myotoxicity.
The clinical and financial consequences of adverse drug reacti ns (ADRs) are high, accounting for
an estimated 6.5% of hospital admissions [3]. Interestingly, for several of the drugs often implicated
in causing hospitalisation, PGx guideline recommendations are now available, such as for warfarin,
antiplatelet agents and opioid analgesics [4]. In addition to serious ADRs leading to hospitalisation,
it is also known that poor drug tolerability (for example due to mild adverse events) is associated with
lower compliance [5], which increases the chances of reduced efficacy and increased medicines wastage.
It is estimated that over 98% of individuals carry at least one pharmacogenetic variant [6].
Importantly, the majority of prescribing and dispensing of medicines happens in primary care,
and recent studies in both the US and UK suggest that over 60% of patients within the primary care
setting are prescribed a medication with a PGx recommendation [7,8]
The Dutch Pharmacogenomics Working Group (DPWG) and Clinical Pharmacogenetics
Implementation Consortium (CPIC) are the two most widely recognised expert groups involved in
the development of PGx clinical guidelines. Therapeutic recommendations from CPIC and DPWG,
as well as guidelines written by other groups such as the Canadian Pharmacogenomics Network
for Drug Safety (CPNDS), are curated and housed by the Pharmacogenomics Knowledge Base
(https://www.pharmgkb.org/), and can be accessed online for free by healthcare professionals and
other individuals with an interest. To date, PGx associations with actionable PGx recommendations
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for clinical practice have been developed for just over 80 drugs [9]. Almost two-thirds of these
actionable drug-gene associations involve drug metabolizing enzyme genes, with ~80% of these
being genes encoding cytochrome P450 (CYP) enzymes. A small number of actionable drug-gene
associations involve transporter genes, and just under a third involve genes that influence drug PD
(~5% on-target, ~26% off-target, with almost a third of the latter involving human leukocyte antigen
(HLA) genes). The US Food & Drug Administration (FDA) has also evaluated drug-gene associations,
deeming 47 drugs to have sufficient evidence for PGx therapeutic recommendations and another
16 drugs to have PGx associations that potentially impact clinical safety or response [10]; there is
notably overlap between the drug-gene associations considered actionable by the guideline committees
and the FDA.
A list of drugs (though not exhaustive) commonly prescribed in primary care with PGx guidelines
currently available is outlined in Table 1.
Despite the growing availability of guidelines, adoption of PGx in primary care has been slow.
Nevertheless, a nationwide study from the Netherlands inferred that 1 out of every 19 new prescriptions
in primary care could have undergone an adjustment had PGx data been available [11]. Within the
UK and in many other countries, PGx testing largely remains within the remit of specialist secondary
and tertiary care settings (e.g., with abacavir-HLA B*57:01 testing). Table 2 provides a summary,
albeit non-exhaustive, of recent and large interventional studies that have assessed PGx and are
relevant to primary care.
A recent analysis identified the following pharmacogenes to be most commonly linked to
primary care prescriptions in England: CYP2D6, CYP2C19 and SLCO1B1 (solute carrier organic anion
transporter family member 1B1), followed by CYP2C9, VKORC1 (vitamin K epoxide reductase complex
1), CYP4F2 and HLA-B (8).Therefore, the subsequent sections in this review provide an overview of the
role PGx can play in primary care in the prescribing and monitoring of specific medications related to
these genes. Drug-specific literature searches were conducted between June and October 2020.
Genes 2020, 11, 1337 4 of 29
Table 1. Commonly used drugs in primary care with available pharmacogenomics guidelines.
Class Drug Gene Actionable Result
Guideline Availability Therapeutic
Recommendations 1DPWG CPIC
Lipid lowering agents
Atorvastatin SLCO1B1 rs4145096 (521T > C)
carriers
√
- AD
Simvastatin SLCO1B1
√ √
LD, AD, M
Antidepressants
Citalopram CYP2C19 PM, UM
√ √
LD (PM), AD (PM, UM)
Sertraline CYP2C19 PM, UM
√ √
LD (PM), AD (PM, UM)
Amitriptyline CYP2C19CYP2D6
PM, RM, UM
IM, PM, UM
-
√
√
√
LD (PM), AD (PM, RM, UM)
LD (IM, PM), AD (PM, UM)
Analgesics
Codeine CYP2D6 IM, PM, UM
√ √
AD (UM, PM), M (IM)
Tramadol CYP2D6 IM, PM, UM
√
- AD (IM, PM, UM),ID (IM, PM), LD (UM)
Anti-platelet Clopidogrel CYP2C19 IM, PM
√ √
AD
Anticoagulant Warfarin
VKORC1
CYP2C9
CYP2C region
VKORC1 c.-1639G > A
*2, *3, *5, *6, *8, *11
rs12777823
√
√
√
√
√
LD 2
LD 2
LD
Anticonvulsant Carbamazepine HLA-BHLA-A
HLA-B*15:02 detected
HLA-A*31:01 detected
-
-
√
√
AD, M
AD, M
Antibiotic Flucloxacillin HLA-B HLA-B*57:01 detected
√
- AD, M
Contraception Oestrogen-containingcontraceptives F5
rs6025 (p.R534Q)
carriers
√
- AD
Xanthine oxidase inhibitor Allopurinol HLA-B HLA-B*58:01 detected -
√
AD
1 = Where a drug-gene pair has guidance available from both CPIC and DPWG, the CPIC recommendations are detailed here. 2 = VKORC1 -1639G > A and CYP2C9 alleles are
often combined together into an algorithm, alongside clinical variables, to guide initial warfarin dosing. Please note that CYP2C9 *1/*2 does not lead to recommended warfarin dose
changes unless the VKORC1 -1639A allele is also present, and VKORC1 -1639GA does not lead to a dose change unless a CYP2C9 reduction-of-function allele is also present [9].
AD = alternative drug; CPIC = Clinical Pharmacogenetics Implementation Consortium; DPWG = Dutch Pharmacogenetics Working Group; LD = lower dose; ID = increase dose;
M = consider additional monitoring (e.g., routine CK surveillance for simvastatin); PM = poor metaboliser; UM = ultra-rapid metaboliser;
√
= guideline available; - = no guideline available.
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Table 2. A non-exhaustive summary of recent interventional studies investigating pharmacogenomics of relevance to primary care. 1◦ = primary endpoint,
2◦ = secondary endpoints, RCT = randomised controlled trial, SoC = standard of care treatment.
Study N Genes Treatment Design Duration Intervention Comparator Endpoint Outcome
Greden et al. 2019
(GUIDED) [12] 1167
Panel of 8 genes
(including CYP2C19
and CYP2D6)
SSRI, SNRI, TCA,
other antidepressants,
typical and atypical
antipsychotics
RCT 24 weeks PGx guidedtreatment
Standard of
care treatment
1◦–Symptoms
(8 weeks)
2◦–Response rate and
remission (8 weeks)
1◦–Symptom ↓ of 27.2%
PGx vs. 24.4% SoC
(p = 0.107)
2◦–Response: 26.0% vs.
19.9% (p = 0.013)
Remission: 15.3% vs.
10.1% (p = 0.007)
Perez et al. 2017 [13] 316
Panel of 30 genes
(including CYP2C19
and CYP2D6)
SSRI, SNRI, TCA,
MAOI, other
antidepressants
RCT 12 weeks PGx guidedtreatment
Standard of
care treatment
1◦–% of patients with
sustained response
(12 weeks)
2◦–Responder rate
and side effect burden
(12 weeks)
1◦–38.5% PGx vs. 34.4%
SoC (p = 0.4735)
2◦–Responder rate:
47.8% vs. 36.1%
(p = 0.0476)
2◦–Side effect burden:
68.5% vs. 51.4%
(p = 0.0260)
Bradley et al.
2018 [14] 685
Panel of 10 genes
(including CYP2C19
and CYP2D6)
SSRI, SNRI, TCA,
other antidepressants,
benzodiazepines,
buspirone
RCT 12 weeks PGx guidedtreatment
Standard of
care treatment
Remission & response
depression (12 weeks)
Symptom severity &
response anxiety
(12 weeks)
Depression:
Remission: 35% PGx vs.
13% SoC (p = 0.02)
Response: 73% vs. 36%
(p = 0.001)
Anxiety:
Symptom ↓ of 54% vs.
42% (p = 0.02)
Response: 63% vs. 50%
(p = 0.04)
Pirmohamed et al.
2013 (EU-PACT) [15] 455 CYP2C9 and VKORC1 Warfarin RCT 12 weeks
PGx guided
treatment
Standard of
care treatment
1◦–% of time in INR
range 2.0 to 3.0
1◦–67.4% PGx vs. 60.3%
SoC (p < 0.001)
Kimmel et al. 2013
(COAG) [16] 1015 CYP2C9 and VKORC1 Warfarin RCT 28 days
PGx guided
treatment
Clinical dosing
algorithm
1◦–% of time in INR
range 2.0 to 3.0
1◦–45.2% PGx vs. 45.4%
SoC (p = 0.91)
Gage et al., 2017
(GIFT) [17] 1650
CYP2C9, VKORC1
and CYP4F2 Warfarin RCT
PGx guided
treatment
Clinical dosing
algorithm
1◦–composite of
major bleeding, INR
≥ 4, death (all in
30 days) or VTE
(in 60 days)
1◦–10.8% PGx vs. 14.7%
SoC (p = 0.02)
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Table 2. Cont.
Study N Genes Treatment Design Duration Intervention Comparator Endpoint Outcome
Pereira et al. 2020
(TAILOR-PCI) [18] 5302 CYP2C19 Clopidogrel RCT 12 months
PGx guided
oral P2Y12
inhibitor
treatment
Standard of
care (Clopidogrel)
1◦–composite of
cardiovascular death,
myocardial infarction,
stroke, stent
thrombosis, and
severe recurrent
ischemia (12 months)
1◦–in 4.0% PGx LOF
carriers vs. 5.9% SoC
LOF carriers (p = 0.06)
Claassens et al. 2019
(POPular) [19] 2488 CYP2C19 Clopidogrel RCT 12 months
PGx guided
oral P2Y12
inhibitor Tx
Standard of care
(Ticagrelor or
prasugrel)
1◦–Net adverse
clinical events (12
months)
1◦–Major or minor
bleeding (12 months)
Net events: 5.1% PGx
vs. 5.9% SoC (p < 0.001
for noninferiority)
Bleeding: 9.8% vs.
12.5% (p = 0.04)
Ko et al. 2015 [20] 2926 HLA-B*58:01 Allopurinol Cohort 9 months
Allopurinol
avoided in
HLA-B*58:01
+ve patients
Allopurinol given
in HLA-B*58:01-ve
patients
1◦–Incidence of
SCARs in cohort
compared to
historical national
average
1◦–No cases of SCARs
in prospective cohort
(within 9 month follow
up) vs. 7 cases to be
expected based on
historical average (0.3%
per year), p = 0.0026
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2. Antidepressants
Prescribed for a variety of indications, the number of prescriptions for antidepressants in the
UK primary care sector is increasing annually [21]. Whilst they are effective therapies, these drugs
have variable success rates [22], with up to 50% of patients nonresponsive to treatment. Some of this
heterogeneity in response may be accounted for by PGx variation.
In the UK, selective serotonin re-uptake inhibitors (SSRIs) account for over 50% of primary care
antidepressant prescriptions [23]; tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake
inhibitors (SNRIs) and atypical antidepressants (e.g., mirtazapine) are also utilised.
There are 57 putatively functional CYP genes within the human genome, of which around 12
are involved in the biotransformation of 70–80% of all therapeutics used in clinical practice [24].
Most antidepressants are, in some part, metabolized via the CYP enzyme system, with CYP2D6 and
CYP2C19 [25] widely regarded as the most influential enzymes for antidepressant biotransformation.
CYP2D6 is highly polymorphic with over 100 allelic variants recorded [26]. Due to the number
of possible diplotypes within a population the translation of genotype to phenotype for CYP2D6 is
often performed using an “activity score” wherein alleles are given a numeric value based on their
functionality and the sum of the values present in an individual is subsequently categorised into one of
the following “metaboliser phenotypes”: ultra-rapid metabolizer (UM), extensive (normal) metabolizer
(EM), intermediate metabolizer (IM), and poor metabolizer (PM) [27].
Allelic frequencies in CYP2D6 vary substantially across populations. The most common
non-functioning variant, CYP2D6*4 (rs3892097, 1846G > A), which is a splicing defect, is found
at the highest frequency within Caucasian populations [28]; related to this observation Caucasian
populations have a higher frequency of PMs (around 5–10%) compared to Asian and African-American
populations. CYP2D6 is also subject to copy number variation (CNV) that can lead to deletion of a
CYP2D6 allele (*5) or CYP2D6 duplication or multiplication; whilst the former decreases CYP2D6
function, an increased number of functional CYP2D6 alleles results in the UM phenotype (*xN).
UMs are less frequent in Caucasian populations at approximately 2%, but the frequency of UMs has
been noted to be much higher in other specific populations, such as those with North African ancestry
(c.25%) [29].
Studies have demonstrated that the presence of the CYP2D6*4 allele in PMs correlated to
increased side effect frequency with some antidepressants including venlafaxine [30] and lower dose
requirements of SSRIs and TCAs (e.g., amitriptyline, nortriptyline; see below) [31]. Additionally,
studies have indicated that CYP2D6 UMs taking paroxetine have low plasma concentrations in
comparison to EMs [32] and this may be a risk factor for therapeutic failure. In the case of both
fluvoxamine and paroxetine, the CPIC guideline highlights the possibility of ADRs potentiated by
higher plasma concentrations in CYP2D6 PMs [33]. Some evidence exists to correlate increased ADRs
with mirtazapine in CYP2D6 IM and PM patients [34,35]. However, at this time, no clinically actionable
PGx recommendation exists for mirtazapine.
CYP2C19 is similarly highly polymorphic: 34 conventional star alleles are currently recognised [36]
and over 2000 CYP2C19 variants have been identified, although the majority are intronic [37]. The most
prevalent reduction-of-function (ROF) allele is *2 (rs4244285, c.681G > A), a splice defect, followed by
*3 (rs4986893, c.636G > A) which results in a premature stop codon. CYP2C19*2 is most common in
individuals of Asian ancestry with minor allele frequencies (MAFs) of 31–36% [38], whilst occurring in
~16% of African and European individuals. CYP2C19*3 occurs in ~6% of East Asian individuals, but is
rare in African and European populations. Conversely, CYP2C19*17 (rs12248560), which is a common
variant in the promotor region of the gene, is associated with increased transcription and enzymatic
function [39].
Similar to CYP2D6, individuals can be categorised according to genotype into anticipated
CYP2C19 EMs (*1/*1 wild-type), IMs (one ROF allele), PMs (two ROF alleles), and UMs (*17/*17).
Unlike conventional CYP2D6 phenotype categorisation, a CYP2C19 rapid metaboliser (RM, *1/*17)
phenotype category is also recognised with functionality between EMs and UMs.
Genes 2020, 11, 1337 8 of 29
Sertraline, citalopram and escitalopram are all extensively metabolised by CYP2C19 and, in PMs,
elevated plasma concentrations may lead to potential ADRs [40,41]. Presently, however, a formal drug
label warning only exists for escitalopram, which recommends a reduced starting dose for CYP2C19
PMs due to the risk of QT interval prolongation [42].
Amitriptyline undergoes CYP2C19-mediated demethylation to its active metabolite, nortriptyline,
which is also available on prescription. Whilst both are classed as TCAs, amitriptyline blocks
serotonin and noradrenaline reuptake equally, whereas nortriptyline inhibits noradrenaline uptake
more potently [43]. As a result, CYP2C19 PMs are expected to show reduced conversion to nortriptyline,
increased systemic exposure to amitriptyline and an increased risk of amitriptyline-related side
effects [44]. Although TCAs are now more commonly used at lower doses for the treatment of
neuropathic pain, rather than for major depressive disorder, the CPIC guidelines for amitriptyline
still recommend consideration of alternative therapy in CYP2C19 UMs due to an increased risk of
treatment failure irrespective of indication [45]. Additionally, amitriptyline and nortriptyline also
undergo CYP2D6 metabolism to a less active metabolite. Whereas CYP2C19 influences the ratio
of metabolites, CYP2D6 plays a greater role in drug clearance. This may lead to raised plasma
concentrations of amitriptyline and nortriptyline in CYP2D6 PMs or in patients co-administered a
CYP2D6 inhibitor [46]. CPIC guidelines therefore recommend a lower starting dose when used at
dosing ranges for depression [47].
A recent meta-analysis of five randomised clinical trials (RCTs) reported that patients receiving
PGx guided dosing were 1.71 (95% CI: 1.17–2.48, p = 0.005) times more likely to achieve symptom
remission for major depressive disorder (MDD) than those on standard care [48]. Details of some of
the most recent RCTs are in Table 2.
While there is still work to be done on the utilisation of PGx in antidepressant prescribing, there are
multiple potential benefits to having PGx information at hand when selecting treatments. An analysis
of UK healthcare data from 2016 identified that the age categories with highest antidepressant use
were ages 55–64 and 75–84 [49]. Additionally, the same data set demonstrated an increasing trend for
polypharmacy with increasing age, particularly in the over 75-years-old age bracket. PGx testing has
the potential to circumvent some of the risks associated with polypharmacy by guiding the prescribing
of suitable medications [50].
In addition to patient benefits, analyses have shown that utilising PGx information in mental
health prescribing may offer significant financial savings via a reduction in the number of failed
treatments and subsequent medicines wastage [51].
3. Opioid Analgesics
Codeine and tramadol are commonly prescribed weak opioid analgesics indicated for mild
to moderate (non-neuropathic) pain; they are positioned on the second rung of the World
Health Organisation’s three step pain ladder. Codeine is an inactive prodrug; 0–15% undergoes
O-demethylation catalysed by CYP2D6 to form active morphine, which has an affinity for the
µ-opioid receptor 200-fold more than that of parent codeine [52]. Similarly, tramadol undergoes
CYP2D6-mediated O-demethylation to O-desmethyltramadol [53], which has an affinity for the
µ-opioid receptor that is also significantly higher than that of tramadol [54]. Whereas the majority of
codeine’s analgesic effect stems from morphine agonism on opioid receptors, for tramadol, the analgesia
conferred by O-desmethyltramadol agonism of the µ-opioid receptor is complemented by inhibition of
serotonin and noradrenaline reuptake by parent tramadol.
In CYP2D6 EM individuals, at least 80% of codeine metabolism results in inactive metabolites,
with around 5–10% undergoing biotransformation into morphine [55]. This percentage increases in
UMs [56] whilst, in PMs, there may be very little if any conversion (52). PK and PD studies have
demonstrated that the increased codeine biotransformation in CYP2D6 UMs can result in opiate
toxicity even with low doses of codeine [57]. Conversely, CYP2D6 PMs are likely to obtain little
to no therapeutic benefit [58]. In addition, due to the heterogeneity in CYP2D6 allele functionality,
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some patients within the broad EM category may also experience an increased number of adverse
events compared with others. These “ultra-rapid EMs” have alleles leading to a greater activity score,
but which still fall within the EM activity score reference range, and thus ideally require lower doses to
circumvent possible ADRs [59].
The PGx of codeine received international attention following reports of infant opiate toxicity from
higher levels of morphine in the breast milk of UM mothers. Reviews of this phenomenon resulted in
amended FDA and European Medicines Agency (EMA) guidance to avoid the use of codeine when
breastfeeding [60].
Similarly, regulatory changes followed case reports of children with obstructive sleep apnoea
receiving codeine post-tonsillectomy and/or adenoidectomy leading to codeine toxicity and fatalities,
with these children having evidence of being CYP2D6 UMs [61,62]. This led to blanket regulation
from authorities such as the UK Medicines and Healthcare products Regulatory Agency (MHRA) [63]
restricting the use of codeine in children under 12 irrespective of CYP2D6 metaboliser status.
This same MHRA guidance extends to cover all patients (i.e., 12 years and older) with a documented
CYP2D6 UM status, although in practice this is seldom known. Both CPIC and the DPWG have
developed PGx guidelines for codeine that advocate avoiding codeine in UM and PM patients.
However, there are nuanced differences between these recommendations. Most pertinently, in UMs,
CPIC recommends simply avoiding codeine, whereas the DPWG guidance suggests no additional
action is required in UM patients that receive lower doses of codeine and have no additional risk factors
(e.g., concomitant CYP3A4-inhibiting drugs) that would predispose to exaggerated biotransformation
to morphine.
In addition to the influence of CYP2D6, there is emerging evidence for the influence of
polymorphisms within other genes including the µ-opioid receptor gene, OPRM1, and the phase
2 metabolising enzyme UGT2B7 [64]. While associations with variation in these genes remain
inconclusive, they are important areas for future research.
Within the UK, the use of the weak opioid tramadol has increased over the past two decades [65].
In keeping with codeine, studies have demonstrated a probable reduced efficacy with tramadol in
CYP2D6 PMs patients and, additionally, a lower risk of ADRs [66]. Again, the risk of ADRs including
potentially severe reactions appears greater in UMs [67,68]. A systematic review of the CYP2D6*10
C188T polymorphism which included 9 studies and 809 subjects showed a relationship between this
polymorphism and pharmacokinetics of tramadol (half-life, AUC and clearance) and analgesic effect,
but not with the adverse effects of nausea and vomiting [69].
Although CPIC has yet to develop guidance for tramadol, the DPWG guidelines recommend
avoiding tramadol in UMs or, if not possible, using just 40% of the standard dose, to minimise the risk of
opioid receptor-mediated ADRs. For PMs, an increased alertness to reduced effectiveness is primarily
recommended. This is because it is difficult to predict the influence of decreased CYP2D6 metabolism
on the overall analgesic effects experienced by an individual, because the resulting increased proportion
of parent tramadol to O-desmethyltramadol may enable the potentiated SNRI properties of parent
tramadol to mitigate some of the lost O-desmethyltramadol opioid receptor-mediated analgesic effects.
4. Statins
Statins are first line lipid-lowering agents for both primary and secondary prevention of
cardiovascular disease, are widely prescribed, and are generally safe and well tolerated. Statins are,
however, associated with an increased risk of type 2 diabetes mellitus and muscle toxicity, which is
phenotypically heterogeneous ranging from myalgias with normal plasma creatine kinase (CK,
~5% of individuals [70]) to infrequent myopathies to rare rhabdomyolysis, and finally extremely rare
immune-mediated necrotizing myopathy (IMNM) [71]. A recent study [72] showed that the risk of
myopathy (CK > 10 × the upper limit of normal) with simvastatin was 9 per 10,000 person-years
of therapy. Independent risk factors for myopathy included simvastatin dose, ethnicity, sex, age,
body mass index, medically treated diabetes, and concomitant use of certain drugs (niacin-laropiprant,
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verapamil, β-blockers, diltiazem and diuretics), which collectively predicted more than a 30-fold risk
difference between the top and bottom thirds of a clinical myopathy score. This risk score was less
strongly associated with milder myopathy, and not associated with reports of any muscle symptoms,
and so the authors concluded that muscle presentations other than myopathy were unlikely to be
related to statins [73].
Statins competitively inhibit 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR)
in the liver, resulting in decreased circulating low-density lipoprotein cholesterol (LDL-C).
Organic anion-transporting polypeptide 1B1 (OATP1B1) is a liver-specific transporter expressed
on the basolateral (sinusoidal) side of hepatocytes [74], is encoded by SLCO1B1 and is involved in
hepatic uptake of statins and other drugs (e.g., letermovir [73]). A common ROF SLCO1B1 missense
variant, rs4149056 (c.521T > C, p.V174A, present in SLCO1B1*5, *15 and *17), is associated with a 221%
increased systemic exposure to simvastatin acid in 521CC compared to wild-type 521TT individuals.
Moreover, the C allele is associated with elevated exposures to all statins, except fluvastatin, albeit to
lesser extents [75]. For example, the corresponding increase with atorvastatin is 145%. The MAF of
rs4149056 in African, East Asian and European populations is 1%, 12% and 16%, respectively.
Importantly, it was shown in a genome-wide association study (GWAS) that 521TC and
521CC patients taking simvastatin 80mg daily had an odds ratio (OR) for myopathy of 4.5
(95% confidence interval (CI) 2.6–7.7) and 16.9 (95% CI 4.7–61.1) compared to wild-type patients,
respectively [76]. In 521TC patients on simvastatin 40mg, the relative risk was 2.6 (95% CI 1.3–5.0).
Furthermore, the 521C allele is associated with a two-fold increase in statin intolerance in patients
predominantly taking simvastatin, and this intolerance can reduce lipid-lowering efficacy [77]. Thus,
the strength of SLCO1B1-myotoxicity association increases with 521C allele dose, simvastatin dose and
myopathy severity.
Several other studies [78] including a recent large-scale GWAS [79] have replicated the
simvastatin-521T > C association. The consistent association with simvastatin mirrors the PK
observations that 521T > C has the largest impact on simvastatin exposure, reflects the high
prevalence of simvastatin use in clinical practice leading to reliance on simvastatin myotoxicity
cases in research studies, and the in vitro observations that simvastatin (lactone) is particularly
myotoxic [80]. Elevated simvastatin systemic exposure presumably increases skeletal muscle exposure,
predisposing to myotoxicity by mechanisms that are incompletely understood but likely to include
mitochondrial dysfunction, calcium signalling disruption and reduced prenylation.
The evidence for an association between SLCO1B1 521T > C and other statins is less clear.
Some studies have suggestively associated 521C with atorvastatin myotoxicity [81–83], but others
found no association [84–86]. Interestingly, a recent study in patients on high dose atorvastatin for
secondary prevention found 521C was associated with both muscular symptoms and atorvastatin
intolerance, suggesting that 521T > C may be more relevant in patients on high dose (e.g., 80 mg)
atorvastatin [87]. For rosuvastatin, 521C was not associated with myalgias in patients of European
descent [88], but recently has been associated with myotoxicity (myalgias to rhabdomyolysis) in Chinese
ancestry patients [89]. SLCO1B1 521T > C has not been associated with pravastatin myotoxicity.
A recent international whole-exome sequencing endeavour of patients with statin (most commonly
simvastatin) myopathy identified no novel variants [90]. Nevertheless, a candidate missense variant
(rs12975366, p.D247G) within leukocyte immunoglobulin-like receptor subfamily B member 5 (LILRB5)
was recently associated with statin myotoxicity, including intolerance and myalgia, implicating the
immune system in these more mild phenotypes [91]; an intervention study is underway [92]. Moreover,
CYP3A4*22 and CYP3A5 non-expressors have been associated with modestly elevated simvastatin
exposure [93], CYP3A7*1C with increased atorvastatin hydroxylation [89], and ABCG2 rs2231142
(c.421C > A) with elevations in exposure to simvastatin, atorvastatin, fluvastatin and especially
rosuvastatin [75,94]. Nevertheless, despite signals, these candidate genes and others (e.g., ABCB1)
have not been consistently associated with statin myotoxicity across studies. Similarly, CYP3A4 [95],
CYP3A5 [96] and CYP2D6 [97] have been investigated as potential biomarkers of statin efficacy,
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but results have varied and, of note, none were identified in a GWAS meta-analysis of statin
lipid-lowering efficacy [98]. Nevertheless, the influence of more complex interactions, such as
those involving combined genetic variation in both SLCO1B1 and CYP and/or other transporter genes,
on statin pharmacokinetics and clinical effects, warrants further study. In addition, CYP2C9 ROF
variants have been associated with increased adverse events (primarily myotoxicity [99]) and potentially
increased lipid-lowering efficacy [100]. Fluvastatin has arguably received less research attention than
simvastatin and atorvastatin, yet CYP2C9 is important in fluvastatin’s metabolism, and so follow up
studies are warranted to further investigate these findings.
SLCO1B1 521T > C has been associated with the spectrum of myotoxicity, at least for simvastatin,
except for IMNM. A subtype of IMNM is anti-HMGCR myopathy [101]; most patients with
anti-HMGCR myopathy have a history or statin exposure, develop muscle weakness with highly
elevated CK levels that persist despite statin cessation, are identified by the presence of circulating
anti-HMGCR autoantibodies that can be directly pathogenic, and normally require treatment with
immunosuppressive drugs or intravenous immunoglobulins [102]. Interestingly, HLA-DRB1*11:01
has been significantly associated with anti-HMGCR myopathy [103,104] with estimated OR of
~25–57 dependent on ethnicity. Whilst this HLA association may catalyse research into underlying
mechanisms and aid diagnosis, the rarity of anti-HMGCR myopathy suggests this PGx association will
not have utility in guiding statin initiation.
Both CPIC and the DPWG have developed clinical guidelines for simvastatin-SLCO1B1 [105,106],
and the DPWG have also developed atorvastatin-SLCO1B1 guidance. In patients that carry 521C,
they recommend starting an alternate statin or using a lower simvastatin dose. For atorvastatin,
the DPWG guideline recommends an alternative statin in 521C carriers that have additional clinical
myotoxicity risk factors. Nevertheless, few patients are now started on simvastatin 80 mg following
an FDA warning about its increased myopathy risk [107]. Interestingly, a recent randomized trial in
159 patients with previous statin myalgia has demonstrated that providing SLCO1B1 521T > C genotype
with recommendations increases statin re-initiation in primary care [108]. As muscle symptoms are
associated with statin discontinuation and non-adherence [5], which in turn increase the risk of
cardiovascular events [109], 521T > C genotyping may help reduce cardiovascular events as well as
myotoxicity in clinical practice, although this remains to be substantiated.
5. Clopidogrel
Clopidogrel is an antiplatelet drug indicated in acute coronary syndrome (ACS),
percutaneous coronary intervention (PCI), stroke, transient ischaemic attack (TIA), peripheral artery
disease (PAD) and atrial fibrillation (AF). Clopidogrel is a prodrug: of the ~50% absorbed, ~85% is
rapidly hydrolysed to inactive clopidogrel carboxylic acid via carboxylesterase 1 (CES1) and ~15%
undergoes a two-step oxidative biotransformation to produce the active thiol metabolite that irreversibly
inhibits platelet P2Y12 receptors [110].
CYP2C19 is the only CYP substantially involved in both oxidative steps, contributing 45% and 21%
to the first and second steps, respectively [111]. CYP2C19 ROF alleles are associated with decreased
levels of circulating clopidogrel active metabolite [112] and increased ex vivo high on-treatment
platelet reactivity (HTPR) [113]. A meta-analysis of 9685 patients, of whom 91% had undergone PCI
(55% ACS), demonstrated that CYP2C19 ROF alleles were associated with an increased risk of major
adverse cardiovascular events (MACE) and stent thrombosis, with a gene-dose trend evident [114].
However, a second meta-analysis assessing CYP2C19 genotype and cardiovascular outcomes in 26,
251 individuals found no overall association with cardiovascular outcomes after exclusion of small
studies, although an increased risk of stent thrombosis remained evident [115]. This meta-analysis
included a wider spectrum of indications for clopidogrel, including atrial fibrillation. To resolve these
discrepant observations, clopidogrel indication-specific PGx has been posited. Thus, these (mostly)
observational data have been considered to support an association between CYP2C19 ROF variants
and cardiovascular events in post-PCI patients, because this patient population’s high baseline risk for
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cardiovascular events makes them more susceptible to suboptimal treatment, but does not support
an association in other (mainly cardiac) settings where the overall benefit of clopidogrel is modest
anyway [116].
To investigate whether interventions based on CYP2C19 ROF alleles improve clinical outcomes,
two large randomized clinical trials (RCTs) have been undertaken and recently reported (Table 2) [18,19].
The Patient Outcome after primary PCI (POPular) Genetics trial included 2488 patients with
an ST-elevation myocardial infarction (STEMI) that underwent primary PCI with stent insertion
and compared standard-treatment (ticagrelor or prasugrel) to a genotype-informed antiplatelet
strategy that allocated ticagrelor/prasugrel to CYP2C19*2 or *3 carriers and clopidogrel to noncarriers.
POPular Genetics reported the genotype strategy was non-inferior to standard-treatment for net adverse
clinical events (MACE plus major bleeding, p < 0.001 for noninferiority), but reduced (mostly minor)
bleeding (hazard ratio (HR) 0.78, 95% CI 0.61–0.98, p = 0.04). The Tailored Antiplatelet Initiation to
Lessen Outcomes Due to Decreased Clopidogrel Response after PCI (TAILOR-PCI) RCT [18] recruited
5302 patients undergoing PCI with stent insertion (for ACS or stable coronary artery disease) and
compared standard-treatment clopidogrel to an equivalent CYP2C19-informed antiplatelet strategy to
that used in POPular Genetics. The primary result of TAILOR-PCI was a reduction in first MACE in
the genotype strategy arm compared to the standard (clopidogrel) arm, although it narrowly missed
statistical significance (HR 0.66, 95% CI 0.43–1.02, p = 0.06). A pre-specified sensitivity analysis showed
a significant reduction in all cumulative MACE events (HR 0.60, 95% CI 0.41–0.89, p = 0.01) with
genotyping. There was no difference in bleeding risk between arms. Of note, the power to detect a
difference in TAILOR-PCI was lower than originally planned because the event rate was lower than
anticipated, in keeping with use of newer generation drug-eluting stents [18].
CYP2C 19*17 has been associated with decreased HTPR, and inconsistently with increased bleeding
risk and reduced MACE [117]. Given the inconsistent findings, less observational research has focused
on *17 compared to CYP2C19 ROF alleles, and that *17 was not included in the POPular Genetics or
TAILOR-PCI primary analyses, the clinical relevance of *17 remains undetermined.
There has been an increased focus recently on the impact of CYP2C19 ROF alleles in patients
following a stroke. A recent meta-analysis of studies of patients prescribed clopidogrel for ischaemic
stroke/TIA found CYP2C19 ROF carriers had an increased risk of recurrent stroke and MACE [118].
CYP2C19 ROF alleles have also been associated with increased in-stent restenosis in patients with
PAD [119]. On the other hand, a genetic analysis of the large EUCLID trial (n = 13,885) that recruited
patients with symptomatic PAD reported no difference in cardiovascular outcomes between patient
subgroups with different CYP2C19 genotypes [120]. However, EUCLID excluded CYP2C19 PM patients
from entry into the trial, limiting interpretation of these findings.
Beyond CYP2C19, there is growing evidence for a role of CES1 in clopidogrel PGx. CES1 catalyses
clopidogrel to its inactive metabolite; the variant allele of rs71647871 (p.G143E, MAF ~1%) in CES1
has been associated with increased circulating clopidogrel active metabolite, reduced ex vivo platelet
reactivity, and a nonsignificant trend towards decreased MACE [121]. Moreover, the variant allele
of CES1 rs2307240 (p.S75N, MAF ~5%) was recently associated with reduced subsequent MACE in
clopidogrel-treated ACS patients [106].
Both CPIC [121] and DPWG (106) have produced clinical guidelines for clopidogrel-CYP2C19:
CPIC focuses on ACS patients undergoing PCI, and DPWG on PCI for any indication, as well as stroke
and TIA. The main recommendation is alternative antiplatelet therapy in those with CYP2C19 ROF
alleles, although the DPWG guidance also permits doubling the dose of clopidogrel in CYP2C19 IMs.
A multi-site real world implementation of CYP2C19 genotyping to guide antiplatelet stratification after
PCI (n = 1815) has been reported, and importantly demonstrated clinical benefit [122]. On balance,
taking all evidence together, we contend that clinical implementation of clopidogrel-CYP2C19
genotyping is justifiable and beneficial.
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6. Warfarin
The oral vitamin K antagonist, warfarin, is indicated to prevent and treat venous thromboembolism
(VTE) and to prevent thromboembolism in atrial fibrillation (AF) and following mechanical heart
valve transplantation. Warfarin is a racemate that competitively inhibits VKORC1 within the vitamin
K cycle, leading to hypofunctional clotting factors II, VII, IX and X. The extent of anticoagulation is
measured by the international normalised ratio (INR) and, for most indications, the target therapeutic
INR is 2.0–3.0 [123]. Warfarin stable dose (WSD) requirements vary ~30-fold between patients [124],
and its narrow therapeutic index underlies warfarin being the third most common drug to lead to
hospitalisation due to ADRs(3). A 10% increase in time outside the therapeutic INR range (TTR) is
associated with increased thromboembolic events and mortality [125], and supratherapeutic INRs
increase the risk of major bleeding [126].
Overall, ~60% of the observed variation in warfarin stable dose requirements can be explained,
and several clinical factors including age, smoking and interacting drugs contribute [127]. However,
genetic factors explain the majority of this observed variation. Specifically, rs9923231 (-1639G > A) in
VKORC1 accounts for 6–25% of observed variation, variation in CYP2C9 another ~15%, and CYP4F2*3
(rs2108622, p.V433M) 1–7% [128–130].
-1639G > A lies within VKORC1′s promoter region; -1639A alters a transcription factor binding
site reducing VKORC1 transcription [131], increasing sensitivity to warfarin and reducing WSD
requirements [132]. The MAF of -1639A in African, East Asian, South Asian and European populations
is ~5%, ~90%, ~15% and ~40%, demonstrating allele reversal in East Asians. The variation in -1639A
MAF perhaps underlies why -1639G > A explains only 6% of WSD variation in African-Americans but
~20–25% in Asian and Caucasian populations [133].
CYP2C9 metabolises the more potent S-warfarin enantiomer and CYP2C9 ROF variants reduce
WSD requirements. CYP2C9*2 (rs1799853, p.R144C) and *3 (rs1057910, p.I359L) are common
ROF alleles in European populations with MAFs of ~12% and ~7%, respectively, and CYP2C9*3
is common in Asian populations (MAF 3–11%). However, CYP2C9*2 is infrequent in Asians (0–3%)
and both are rare or infrequent in African populations (0–3.6% for *2, and 0.3–2% for *3) [134].
Interestingly, distinct warfarin-associated variants have been described in African ancestry patients
(primarily Africa-Americans). CYP2C9*5, *6, *8 and *11 are ROF alleles with a collective frequency
of ~20% in African ancestry individuals [135], but are rare in other ethnicities. All of these variants,
except CYP2C9*8, have been confirmed by meta-analysis to reduce warfarin dose requirements in
black African patients [136]. The non-coding variant, rs12777823, within the CYP2C cluster upstream
of CYP2C18, has also been associated with reduced WSD requirements, independent of CYP2C9 [137].
CYP4F2 mediates removal of active (reduced) vitamin K from the vitamin K cycle. CYP4F2*3 is
associated with lower hepatic CYP4F2 [138] and increased WSD requirements in Asian [139] and
European ancestry patients, but not in those of African ancestry [140,141].
Beyond VKORC1/CYP2C9/CYP4F2, many other candidate genes have been investigated for
their role in variable warfarin dose requirements, although findings have been mostly contradictory,
and not supported by GWAS. Interestingly however, rs7856096 in the folate homeostasis gene,
folylpolyglutamate synthase (FPGS), was identified in African-Americans by exome sequencing and
replicated [142]. It decreases FPGS transcription and is associated with reduced WSD requirements,
although the causative mechanism remains unknown.
Several RCTs have investigated the utility of genetic-guided warfarin dosing algorithms (Table 2).
The largest trial to date, the Genetic Informatics Trial (GIFT), recruited patients initiating warfarin
for elective hip or knee surgery [17]. GIFT compared 808 patients that received genotype-guided
dosing (considering VKORC1 -1639G > A, CYP2C9*2, CYP2C9*3, CYP4F2*3) to 789 that received
clinically-guided dosing. The primary clinical composite endpoint of major bleeding, INR ≥ 4, VTE or
death occurred in 10.8% of patients in the genotyped arm versus 14.7% in the clinically-guided arm
(p = 0.02). The high-risk subgroup of patients (those with a difference of at least 1.0mg/day between
clinically guided and genotype-predicted warfarin doses), which plausibly had a higher number of
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warfarin sensitive alleles, particularly benefitted from genotyping with a larger (7%) increase in TTR.
The findings in GIFT were consistent with the EU-PACT RCT, but not with COAG (Table 2) [15,16,131]
Both CPIC [143] and DPWG have developed warfarin PGx guidelines for commencing
warfarin that recommend validated genetic algorithms (e.g., the EU-PACT loading algorithm [15]
or International Warfarin Pharmacogenetics Consortium (IWPC) algorithm [144]) or percent dose
alterations. Importantly, point-of-care genotype-guided warfarin dosing has been shown to significantly
improve TTR following implementation in real world anticoagulation clinics [145], and appears
cost-effective [16].
The majority of patients investigated have been of European ancestry.As described above,
ethnicity influences the prevalence of warfarin risk alleles, particularly in those of Sub-Saharan African
origin. Thus, ethnicity-specific algorithms have been developed, although prospective testing of these
algorithms is currently limited [146,147]. Moreover, self-reported ethnicity may not represent genetic
ancestry well, especially for admixed individuals [148]. Nonetheless, it has been recently shown that
an individual’s genetic ancestry can be reasonably determined from clinically focused PGx SNP panels
(122 and 243 SNPs) compared with genome-wide genotyping [149]. This approach could stratify
individual’s by genetic ancestry to facilitate implementation of ethnicity-specific warfarin algorithms.
Although warfarin remains commonly prescribed, it is clear that the use of direct oral anticoagulants
(DOACs) is increasing [150]. DOACs are at least as safe and effective as warfarin in the prevention of
stroke in non-valvular AF [151] and monitoring is not required. However, their current high price
restricts access to them in many healthcare systems, and concerns over long term adherence [152],
as well as patient choice, mean they are not suitable for all patients. Interestingly, bleeding risk
appears equivalent between DOACs and warfarin in patients who have no VKORC1/CYP2C9 warfarin
risk alleles [153] or their anticoagulation centre-based TTR is ≥66% [154], and thus anticoagulant
stratification based on VKORC1/CYP2C9 genotypes has been posited [155]. Moreover, no DOAC is
indicated following mechanical heart valve surgery or in those with a creatinine clearance <15mL/min;
thus, further research into the utility of warfarin PGx in these specific settings is warranted.
7. Metoprolol
Metoprolol is a racemate cardioselective β1-adrenoreceptor blocking agent used for indications
including hypertension, heart failure, angina pectoris, arrhythmias and migraine prophylaxis.
Around 70% of an oral dose undergoes metabolism by CYP2D6 to inactive metabolites [156].
Plasma levels of metoprolol have been found to be significantly higher (around 4–5 ×) in CYP2D6 PMs
compared with EMs [157].
Metoprolol decreases cardiac output via negative chronotropic, as well as inotropic effects,
thus reducing heart rate [158]. Retrospective and prospective studies have demonstrated significantly
greater reductions in heart rate in PMs vs. non-PMs [159,160] and an increased risk of bradycardia [161].
Although, there is observed heterogeneity in the incidence of bradycardia between studies, a recent
meta-analysis identified that overall the prevalence of bradycardia is statistically significantly higher in
PMs [162]. Nevertheless, the clinical relevance of this finding is presently unclear, given that many of
the instances of bradycardia have been asymptomatic (e.g., detected on an electrocardiogram performed
as part of a study protocol) with comparatively little reported around symptomatic bradyarrhythmias.
The DPWG guideline for metoprolol in CYP2D6 PM and IM patients suggest a dose reduction
(to 25% and 50% of the standard dose, respectively) where a gradual reduction in heart rate is required
(for example, in chronic heart failure) or symptomatic bradycardia occurs. As there may be increased
conversion to inactive metabolites in UM patients blunting the efficacy of metoprolol, dose increases
beyond the usual maximum dose or selection of an alternative β-blocker (indication dependent)
may be required [106]. While other β-blockers including carvedilol, nebivolol and propranolol
are also metabolized by CYP2D6, the extent of their CYP2D6-dependent metabolism is less than for
metoprolol [163]. Moreover, atenolol is not metabolised, and bisoprolol undergoes balanced elimination
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with half excreted via the kidneys and the other half undergoing metabolism by CYP3A4 and CYP2D6;
CYP2D6 does not appear to be an important predictor of bisoprolol exposure or function [164,165].
8. Allopurinol
The xanthine oxidase inhibitor, allopurinol, is commonly prescribed in primary care for the
prophylaxis of gout; it is also indicated in other hyperuricaemic conditions including tumour
lysis syndrome. Although allopurinol is generally well tolerated, severe cutaneous adverse
reactions (SCARs) represent a rare (0.1–0.4% of patients) but serious allopurinol ADR. The SCARs,
Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia
and systemic symptoms (DRESS), have all been reported following allopurinol exposure [166].
SCARs have overlapping clinical features including eosinophilia, hepatic/renal dysfunction and
rash or skin detachment. SJS and TEN are considered to represent different severities along a continuum
of the same disease process; SJS is diagnosed when≤10% body surface area is affected, TEN when >30%
is affected, and an overlap syndrome occurs with 10–30% body surface area involvement [167].
Allopurinol is the most common cause of SCARs in Europe [168]. Furthermore, SCARs have high
morbidity and mortality rates [167,169] and the mortality specifically from allopurinol-associated
SCARs has been reported to approach 25% [168,170].
Studies have shown strong associations between allopurinol-related SCARs and carrying
HLA-B*58:01 [171,172]. In an interventional cohort study in Taiwan, genotyping HLA-B*58:01 and
giving alternate treatment to HLA-B*58:01 positive patients, whilst HLA-B*58:01 negative patients
received allopurinol, resulted in no SCAR cases, compared to an estimated seven cases based on the
historical average (p = 0.0026) [20].
The allopurinol SCAR-HLA-B association is considered to be a type IV hypersensitivity reaction
and is T-cell mediated [173]; typically, such reactions occur up to 3 months after drug initiation
(most cases occurring within 8–9 weeks [174] and are delayed in onset (as opposed to anaphylactic
reactions with other drugs which are immediate) [175]. Other identified clinical factors that increase the
risk of allopurinol SCAR include older age, female sex, chronic kidney disease and higher starting doses,
which all plausibly increase systemic exposure [176]. Following oral administration, allopurinol is
almost completely metabolised into its active metabolite, oxypurinol, which has an elimination half-life
of 15 h, compared to 1–2 h for allopurinol [177]. Regarding immunopathogenesis, both allopurinol and
oxypurinol have been shown to directly bind HLA-B*58:01 and Arg97 of HLA-B*58:01 is a plausible
binding site for oxypurinol via hydrogen bond formation [178]. Oxypurinol-sensitive T-cell lines
can have mixed populations of CD4+ and CD8+ T-cells. Moreover, in vitro T-cell activation assays
after culturing peripheral blood mononuclear cells from patients with previous allopurinol-associated
SCARs demonstrated that oxypurinol increased granulysin in a concentration- and time-dependent
manner, but allopurinol and febuxostat did not, indicative of oxypurinol-induced T-cell activation [179].
Sequencing the T-cell receptors demonstrated that clonotype-specific T-cells that secrete granulysin
in response to oxypurinol likely participate in the pathogenesis [179]. Overall, these observations
are consistent with the p-i hypothesis (direct pharmacological interaction between a drug/metabolite
and HLA molecules) whereby allopurinol-associated SCARs are the result of MHC Class I-driven
activation of oxypurinol-specific T-cell clones through an antigen-processing independent route.
The frequency of HLA-B*58:01 varies with ethnicity, but occurs at a higher prevalence in East
Asian populations [180]. HLA-B expression is co-dominant and individuals need only carry one copy
of HLA-B*58:01 to be at increased risk of SCARs. Accordingly, genotyping results are usually reported
as HLA-B*58:01 positive, where one of more copies of the allele are detected, or negative where the
allele is not detected. This association is now mentioned within the European drug label and CPIC
guidelines for allopurinol advise against its use in known HLA-B*58:01 carriers [170,181]
More generally, associations between specific HLA alleles and serious ADRs due to at least
24 different drugs have now been reported [182], highlighting the importance of the HLA locus to
immune-mediated type IV hypersensitivity reactions. Like, allopurinol, several of these associations
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are very strong (e.g., odds ratios in the tens-thousands) and related to drug-induced skin injury, such as
between carbamazepine-HLA-B*15:02 and SJS-TEN, and carbamazepine-HLA-A*31:01 that is associated
with both specific SCARs (DRESS and SJS-TEN) and more mild but common (up to 10% of patients [183])
maculopapular exanthema [184]. HLA alleles have also been associated with drug-induced liver
injury, such as between flucloxacillin and HLA-B*57:01 [185]. Of note, HLA-B*57:01 is also associated
with abacavir hypersensitivity syndrome [186]. As previously mentioned, HLA-DRB1*11:01 has been
significantly associated with statin-related anti-HMGCR myopathy [103]. These associations provide
mechanistic insight and can aid in preventing or diagnosing a serious ADR.
9. Transitioning to the Future
The current literature demonstrates that many primary healthcare providers including physicians
and pharmacists are hopeful about the role of PGx in enhancing the care of their patients [187,188]
but often highlight that there are still multiple barriers impeding translation into daily practice [189].
Potential pathways of how GPs may encounter PGx tests are shown in Figure 2. Recent studies have
identified that barriers to PGx implementation specifically within primary care include a perceived
lack of evidence for clinical utility, unclear cost effectiveness and reimbursement strategies, how to
educate the primary care workforce regarding PGx, unclear roles and responsibilities particularly
between general practitioners and pharmacists, the need for informatics to support PGx-informed
clinical prescribing decisions, and concerns over the principles of data sharing as well as other ethical,
legal and social implications (ELSI) surrounding PGx [190,191].
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REactions (PREPARE)) within both primary and secondary care settings [192]. This study aims to 
recruit around 7000 patients to determine the clinical utility and cost effectiveness of testing a panel 
Figure 2. Four hypothetical pathways through which GPs may encounter pharmacogenetic tests
within their primary care practice. Pathway 1 is where the GP initiates the test themselves; pathway 2
is where the genetic test is carried out in secondary care and the GP is informed of the test result;
and pathway 3 is where the patient presents to the GP having undertaken a test privately or via a direct
to consumer genetic testing laboratory. Pathways 1–3 represent situations where a single gene/variant
test is undertaken for one gene-drug pair. Pathway 4 represents the situation where the patient has
undergone a panel test or exome/whole genome sequencing, where there is the added complexity of
storing the rest of the genetic data and having the ability to retrieve it, and use it appropriately in a
pre-emptive fashion when a patient is prescribed a new drug(s).
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Efforts to overcome these barriers and facilitate PGx translation are ongoing.
Within Europe, the Ubiquitous Pharmacogenomics Consortium (U-PGx) is undertaking a large,
international implementation project (PREemptive Pharmacogenomic testing for prevention of Adverse
drug REactions (PREPARE)) within both primary and secondary care settings [192]. This study aims to
recruit around 7000 patients to determine the clinical utility and cost effectiveness of testing a panel of
44 PGx variants in 12 genes relevant to 42 drugs for which a DPWG PGx guideline has been developed;
the primary focus of PREPARE is to investigate whether PGx implementation reduces ADRs within
the first 12 weeks of starting one of these 42 drugs, compared to standard care. Similar initiatives
adopting panel-based testing are ongoing around the world, including the Pharmacogenomic Resource
for Enhanced Decisions in Care and Treatment program (PREDICT) in the US, which has pre-emptively
tested over 10,000 patients to date [6]. Moreover, in the UK, the NHS Genomic Medicine Service (GMS)
outlined its plans to have genomic medicine fully integrated into routine practice by 2025 [193].
Despite the cost of genetic tests decreasing, cost-effectiveness remains a concern for PGx
testing. While some drug-gene pairs, such as abacavir-HLA-B*57:01 and allopurinol-HLA-B*58:01,
have demonstrated cost-effectiveness compared with no genetic testing, others such as factor V Leiden
testing prior to oral contraception, have shown mixed and inconclusive results [194]. Panel testing is
the most common form of PGx testing currently being utilised in large scale studies such as PREPARE,
and is likely more cost effective than single gene testing [195]. Although panel testing does not offer
the same in-depth information for a gene compared to whole genome sequencing, its upfront costs
are less, test turnaround times are shorter, and interpretation of gene regions is less complicated,
which arguably makes it a better suited technology for larger scale implementation in the near to
medium term.
Patient focus groups have shown a preference for a familiar healthcare provider to be involved
with delivering PGx services [196]. In addition, the uptake of direct-to-consumer testing is increasing
and so there is a need to upskill the primary care workforce at large to improve its genetic literacy [197].
It is clear that wider implementation of PGx into the primary care sector will be soon upon us, and it
is essential that all areas are able to access the resources to become more comfortable with PGx and
overcome the aforementioned barriers.
One critical area for implementation is the development of appropriate clinical decision support
systems (CDSS) that facilitate use of PGx information at the point of prescribing and, ideally,
integrate this information with other factors routinely considered in the prescribing decision-making
process, such as co-medications and comorbidities. In the UK at least, the widespread and early
adoption of electronic medical patient records in primary care, which are provided by only a handful
of service providers (e.g., EMIS and SystemOne), provide a pre-existing technological infrastructure to
build PGx CDSS into. In contrast, the varying uptake of electronic records in secondary care and the
greater heterogeneity in providers poses additional barriers to implementing PGx in hospital settings.
As the implementation infrastructure for PGx is gradually erected, it will be important to transition
to healthcare learning systems where clinical and research activities are more clearly linked. Thus,
ideally, novel clinically relevant and validated discoveries can then be implemented in a shorter time
frame than currently, and the effects in the real-world of new interventions observed, measured and
iteratively fed back to the research arm to inform future enquiry. A key component of an effective
healthcare learning system will be merging presently disparate data sources together and putting
systems in place to efficiently collect future clinical data as it is generated to enable big data analyses,
and there is little reason why PGx cannot be at the forefront of such endeavours. For example,
combining primary care records with array genetic data at scale within UK Biobank has enabled
recent PGx analysis investigating interactions between 200 drugs and nine genes in 200,000 subjects,
leading to confirmation of several established drug-gene pairs, as well as providing genetic evidence
of more novel associations such as between citalopram and reduced incidence of herpes zoster in
CYP2C19 IMs [198].
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It should be noted that, to date, the majority of PGx associations involve common variants,
including the drug-gene variant associations highlighted in this review. Rare variants (i.e., those with
a minor allele frequency < 1%) are often missed in small clinical studies or GWAS analyses, but some
may have large effects on outcomes [199]. Case studies of rare and serious ADRs have highlighted
the clinical impact of rare variation in pharmacogenes. For example, a recent case report detailed
development of reversible encephalopathy and coma after a paediatric patient received a single dose
of ivermectin, attributable to compound heterozygosity from two nonsense mutations in ABCB1,
which encodes P-glycoprotein [200]. Furthermore, the increasing use of next generation sequencing
(NGS) technologies in national and other large genomic medicine projects heralds a new era for
investigating rare variation at scale. It is currently estimated that, overall, 10–40% of genetic functional
variation in pharmacogenes is attributable to rare ght to account for 9% and 39% of the functional
variation in SLCO1B1 and ABCC1, respectively variation, although it varies considerably between
genes [201]. For example, rare variation is thou Machine learning and other advanced methodologies
will likely be needed to parse this rich sequence data, particularly when combined with other data
types (e.g., clinical and other omics datasets), to aid functional interpretation and variant discovery,
refine genotype-to-phenotype predictions, stratify patient groups, and predict drug response [202,203].
10. Conclusions
The majority of prescribing happens in primary care. Owing to interindividual variation,
some patients experience reduced effectiveness and others ADRs. Extensive research into PGx has
identified and replicated multiple drug-gene pairs, mainly associated with ADRs, with several of the
associated drugs commonly prescribed in primary care. The ongoing development of PGx guidelines
by CPIC, DPWG and others offers a standardised approach to translating drug-gene associations into
actionable prescribing recommendations based on the collective evidence available. Nevertheless,
several barriers still exist to wider adoption of PGx into primary care, although these are gradually
being addressed. Moving forward, a transition towards healthcare learning systems that harness
big data and advanced analytical techniques with implementation of clinically relevant findings is
anticipated to advance patient care. One area for focus is the surge in multimorbidity and related
polypharmacy that multiple primary care and wider healthcare systems are facing. Although further
research is required, it is envisaged that PGx will play a meaningful role in optimising medicines and
managing polypharmacy [50]. Overall, it is hoped that implementation of PGx in primary care will
be a major activity over the next five years, with ongoing PGx discoveries further boosting the case
for implementation.
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